Recent SEC Filing Signals

Ultragenyx is the cleanest September binary in the screen: the FDA accepted the UX111 BLA resubmission and set a September 19, 2026 PDUFA action date for Sanfilippo syndrome Type A, a rare pediatric indication with no approved therapy. The August 5 10-Q showed $125 million of cash plus $167 million of marketable securities at June 30, and SEC data shows six Form 4 filings since June 1. This is high-volatility small/mid-cap biotech, but the catalyst is current, named, and near-term.

Ionis has a September 22, 2026 FDA target action date for zilganersen in Alexander disease, and management has framed the filing as a potential first independent neurology launch. The July 29 10-Q showed roughly $350.1 million of cash and $1.70 billion of short-term investments at June 30, giving the company launch optionality without an obvious near-term financing overhang. The caveat: 25 Form 4 filings since June 1 mean the insider-tape is noisy rather than a simple accumulation signal.

Mirum and Incyte's zilurgisertib program has a September 26, 2026 PDUFA date in fibrodysplasia ossificans progressiva, and Mirum's Q2 balance sheet showed $330.7 million of cash plus $107.6 million of short-term investments. SEC data shows 23 Form 4 filings since June 1, so BioAlpha treats this as a catalyst-plus-liquidity setup rather than an insider-accumulation setup. The signal remains positive because the FDA date is specific, priority-reviewed, and attached to a rare disease market where first/early entrants can reprice quickly.

Scholar Rock's apitegromab BLA is under FDA review for SMA with an approval decision anticipated by the September 30, 2026 PDUFA action date, and the company says it is prepared to launch immediately upon approval. The August 6 10-Q showed $437.1 million of cash and $55.0 million of marketable securities at June 30, while an August 6 424B5 adds fresh financing context. The setup is constructive, but the raise near the catalyst makes position sizing more important than in a pure cash-rich binary.

Roivant subsidiary Priovant has FDA Priority Review for brepocitinib in dermatomyositis with a Q3 2026 PDUFA target action date and management expectation for U.S. launch at the end of September if approved. Roivant's June 30 balance sheet showed $1.25 billion of cash and $2.59 billion of marketable securities, so this is not a financing-risk binary. The signal is lower torque than a single-asset microcap, but the combination of Q3 regulatory timing, 20 Form 4 filings since June 1, and strong cash makes it one of the more credible September setups.

Bristol Myers has a September 30, 2026 PDUFA date for a supplemental NDA that would expand Camzyos into adolescents with symptomatic obstructive hypertrophic cardiomyopathy. The clinical/regulatory signal is real, but BMY's scale dampens single-catalyst trading torque: the company reported $8.72 billion of cash and $2.35 billion of marketable debt securities at June 30. BioAlpha keeps it in the report because it matters to the September FDA tape, but ranks it below smaller-cap binaries.

Rusfertide moved from pending FDA calendar item to an approval-window trade just before the September report cut. Protagonist's Q2 filing showed $420.1 million of cash, $362.5 million of marketable securities, and a collaboration receivable, leaving it well funded around Takeda's partnered launch mechanics. With only four Form 4 filings since June 1, the insider tape is quieter than most September names; the signal is about approval/launch execution and partner economics rather than raw insider clustering.

Revolution Medicines disclosed FDA approval of daraxonrasib for metastatic pancreatic adenocarcinoma on August 26, creating a fresh September commercial-execution setup rather than a pending binary. The August 5 10-Q and August 26 8-K make this one of the cleanest current SEC/FDA intersections in the report, though the initial approval reaction may already be partly priced in. SEC data shows 11 Form 4 filings since June 1, so post-approval insider activity is worth watching into September.

EyePoint is not a September PDUFA name, but it belongs in the September edition because its August 17 DURAVYU Phase 3 topline update landed immediately before the report cut and can keep trading through late-Q3 ophthalmology read-throughs. The June 30 balance sheet showed $110.5 million of cash and $70.0 million of marketable securities, while SEC data shows four Form 4 filings since June 1. BioAlpha rates it neutral because the data catalyst is live but less binary than the PDUFA names above.

Praxis is included as the freshness check: stale September FDA calendars still show relutrigine, but the FDA extended the review from September 27 to December 27, 2026 after additional sensitivity analyses were deemed a major amendment. The Q2 filing showed $474.8 million of cash, $283.8 million of current marketable securities, and $615.3 million of long-term marketable securities, so the delay is not a cash-crisis signal. It is a calendar-risk signal: traders using stale September lists may be anchoring to the wrong binary date.